TY - JOUR
T1 - Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy
T2 - Retrospective Experience
AU - Hoffman-Censits, Jean
AU - Choi, Woonyoung
AU - Bivalacqua, Trinity J.
AU - Pierorazio, Philip
AU - Kates, Max
AU - Lombardo, Kara
AU - Parini, Vamsi
AU - McConkey, David
AU - Trabulsi, Edouard J.
AU - Hahn, Noah
AU - Matoso, Andres
N1 - Funding Information:
Dr Hoffman-Censits reports medical writing services from Genentech, Advisory board for Seattle Genetics, and consultant services for Astra Zeneca. Dr Bivalacqua reports advisory boards for Genesis Biotech and Janssen; and consultant for Feregene, BiogenesisPierorazio: Urogen, and Olympus. Dr Kates reports advisory boards for Genesis Biotech and Janssen; and consultant for Feregene and Pacific Edge. Dr McKonkey reports honoraria from Janssen, H3 Biomedicine, and Rainier; and grant funding from Astra Zeneca, Bioclin, and Rainier Pharma. Dr Trabulsi reports consultant for Pfizer, Astellas, Janssen, and GenomeDx. Dr Hahn reports consultant for Genentech, Merck, Seattle Genetics, Incyte, Janssen, Pieris, Boehringer Ingelheim, Glaxo Smith Kline, Ferring, and Pfizer; and research support from Genetech, Merck, BMS, Seattle genetics, Incyte, Inovio, Janssen, Pieris, Astra Zeneca, and HTG Molecular. The remaining authors have stated that they have no conflicts of interest.
PY - 2021/4
Y1 - 2021/4
KW - Immunotherapy
KW - Neuroendocrine cancer
KW - Platinum refractory cancer
KW - Upper tract
KW - Variant histology
UR - http://www.scopus.com/inward/record.url?scp=85098632520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098632520&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2020.10.009
DO - 10.1016/j.clgc.2020.10.009
M3 - Article
C2 - 33358150
AN - SCOPUS:85098632520
SN - 1558-7673
VL - 19
SP - 176
EP - 181
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 2
ER -